Schwabe, Stefan
Supernus Pharmaceuticals (United States)
3 papers on CoChatORCID 0000-0002-1426-2584
Most cited papers
- Verified
New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties
Yu, C., Garcia-Olivares, J., Candler, S., Schwabe, S., & Maletic, V. (2020) · Journal of Experimental Pharmacology
Attention Deficit Hyperactivity DisorderNeurotransmitter Receptor Influence on Behavior
Cited by 96
- Verified
A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD
Johnson, J. K., Liranso, T., Saylor, K., Tulloch, G., Adewole, T., Schwabe, S., Nasser, A., Findling, R. L., & Newcorn, J. H. (2020) · Journal of Attention Disorders
Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices
Cited by 62
- Verified
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H. (2021) · CNS Drugs
Attention Deficit Hyperactivity DisorderTreatment of Major Depression
Cited by 55
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free